The clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging examination, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of heart sacs. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.